Life Arts

Lapdap - The Breckenridge Connection

By (about the author)     Permalink       (Page 1 of 2 pages)
Related Topic(s): ; ; ; ; ; ; , Add Tags Add to My Group(s)

View Ratings | Rate It

opednews.com

The connection between GlaxoSmithKline's Lapdap and MHRA Chairman Alisdair Breckenridge.

GlaxoSmithKline Plc is scrapping two malaria drugs that may cause anemia, dealing a blow to the global fight against the killer disease, writes Ben Hirschler.

Europe's biggest drugmaker said it was pulling Lapdap from the market in Kenya -- the only place where it has recently been sold.

Lapdap has been linked to reductions in hemoglobin levels in patients with a hereditary enzyme disorder that affects 10 to 25 percent of Africans. Low hemoglobin can lead to anemia which in severe cases may require a blood transfusion.

Lets first start with GlaxoSmithKline and move on to Breckenridge later.

In 2002, talking of Lapdap, GlaxoSmithKline said:

There has been progress in malaria too. In October 2002, we submitted a regulatory application to the UK Medicines Control Agency (MCA) for Lapdap (chlorproguanil/dapsone) for the treatment of the most life threatening type of the malaria. MCA approval will be an important step in making Lapdap available across Africa, where there is great need for new malaria treatments.



Lapdap results from a successful partnership between GSK, the World Health Organization, the University of Liverpool, the London School of Hygiene & Tropical Medicine, and the UK Department for International Development (DFID) This is the first such product development to be directly sponsored by DFID.

The University of Liverpool?

Professor Sir Alasdair Breckenridge, CBE, was most recently Professor of Clinical Pharmacology at the University of Liverpool.

He has been Chair of the Committee on Safety of Medicines (CSM) since 1999, a role which he relinquished when he became chair of the MHRA on its creation in April 2003.

The University of Liverpool has capitalised on 15 years' research by initiating a Public Private Partnership to turn promising lab results into an affordable anti-malarial treatment which can combat drug resistance in Africa.

In the 2003 University of Liverpool Annual Report there is a full page spread 'bigging up' Lapdap. The blurb reads:

Fighting malaria: Professor Peter Winstanley has led the development of a new low-cost anti-malarial drug LapdapTM, designed for sub-Saharan Africa where ‘Plasmodium falciparum’ malaria kills one to two million people every year.

It continues...

GLAXOSMITHKLINE (GSK) WILL MARKET THE AFFORDABLE NEW DRUG.
LAPDAP HAS BEEN DEVELOPED THROUGH A UNIQUE PUBLIC-PRIVATE PARTNERSHIP BETWEEN THE UNIVERSITY, THE WORLD HEALTH ORGANISATION, GSK, THE GOVERNMENT’S DEPARTMENT FOR INTERNATIONAL DEVELOPMENT (DFID), THE LIVERPOOL SCHOOL OF TROPICAL MEDICINE AND THE LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, WITH GRANT SUPPORT FROM THE WELLCOME TRUST.


Breckenridge, along with Peter Winstanley, Stephen Ward, Robert Snow, wrote a paper entitled: Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Next Page  1  |  2

 

Robert Fiddaman is the author of the book, 'The evidence, however, is clear...the Seroxat scandal'. He has been writing about the pharmaceutical industry and medicine regulators for 7 years. His blog, Seroxat Sufferers, has become popular amongst (more...)
 

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

Go To Commenting
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

A Chemical Imbalance - The Serotonin Myth

Billion Dollar Drug Company Law Firm Restructures Connecticut Welfare System

Psychiatric Medication or Play Therapy?

Who Killed Japanese Culture?

Glaxo, Myodil and The UK Regulator

Paxil Study 329 All Over Again?

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
No comments